JP2005516002A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005516002A5 JP2005516002A5 JP2003550726A JP2003550726A JP2005516002A5 JP 2005516002 A5 JP2005516002 A5 JP 2005516002A5 JP 2003550726 A JP2003550726 A JP 2003550726A JP 2003550726 A JP2003550726 A JP 2003550726A JP 2005516002 A5 JP2005516002 A5 JP 2005516002A5
- Authority
- JP
- Japan
- Prior art keywords
- sarm compound
- compound according
- sarm
- muscular atrophy
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940083324 Selective androgen receptor modulator Drugs 0.000 claims 170
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 170
- 150000001875 compounds Chemical class 0.000 claims 166
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 74
- 201000000585 muscular atrophy Diseases 0.000 claims 46
- 208000035475 disorder Diseases 0.000 claims 43
- 201000010099 disease Diseases 0.000 claims 31
- 239000003814 drug Substances 0.000 claims 27
- 239000000126 substance Substances 0.000 claims 17
- 230000001684 chronic effect Effects 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 230000007170 pathology Effects 0.000 claims 15
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 claims 10
- 208000027747 Kennedy disease Diseases 0.000 claims 10
- 150000001204 N-oxides Chemical class 0.000 claims 10
- 210000003169 central nervous system Anatomy 0.000 claims 10
- 239000002207 metabolite Substances 0.000 claims 10
- 239000008188 pellet Substances 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 9
- 230000001419 dependent effect Effects 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 6
- 208000030507 AIDS Diseases 0.000 claims 5
- 208000007848 Alcoholism Diseases 0.000 claims 5
- 208000008035 Back Pain Diseases 0.000 claims 5
- 206010006895 Cachexia Diseases 0.000 claims 5
- 208000031229 Cardiomyopathies Diseases 0.000 claims 5
- 208000018380 Chemical injury Diseases 0.000 claims 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 5
- 206010014561 Emphysema Diseases 0.000 claims 5
- 208000031886 HIV Infections Diseases 0.000 claims 5
- 208000037357 HIV infectious disease Diseases 0.000 claims 5
- 208000002720 Malnutrition Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 5
- 208000027418 Wounds and injury Diseases 0.000 claims 5
- 210000001766 X chromosome Anatomy 0.000 claims 5
- 201000007930 alcohol dependence Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 239000002775 capsule Substances 0.000 claims 5
- 208000020832 chronic kidney disease Diseases 0.000 claims 5
- 239000006071 cream Substances 0.000 claims 5
- 230000006378 damage Effects 0.000 claims 5
- 206010012601 diabetes mellitus Diseases 0.000 claims 5
- -1 elixir Substances 0.000 claims 5
- 239000000839 emulsion Substances 0.000 claims 5
- 208000028208 end stage renal disease Diseases 0.000 claims 5
- 201000000523 end stage renal failure Diseases 0.000 claims 5
- 239000000499 gel Substances 0.000 claims 5
- 230000002068 genetic effect Effects 0.000 claims 5
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 5
- 150000004677 hydrates Chemical class 0.000 claims 5
- 208000015181 infectious disease Diseases 0.000 claims 5
- 230000002458 infectious effect Effects 0.000 claims 5
- 208000014674 injury Diseases 0.000 claims 5
- 208000017169 kidney disease Diseases 0.000 claims 5
- 230000001071 malnutrition Effects 0.000 claims 5
- 235000000824 malnutrition Nutrition 0.000 claims 5
- 201000006938 muscular dystrophy Diseases 0.000 claims 5
- 230000000926 neurological effect Effects 0.000 claims 5
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 5
- 208000005368 osteomalacia Diseases 0.000 claims 5
- 208000001076 sarcopenia Diseases 0.000 claims 5
- 239000000243 solution Substances 0.000 claims 5
- 239000000829 suppository Substances 0.000 claims 5
- 239000000725 suspension Substances 0.000 claims 5
- 239000003826 tablet Substances 0.000 claims 5
- 230000000699 topical effect Effects 0.000 claims 5
- 208000020339 Spinal injury Diseases 0.000 claims 4
- 206010028289 Muscle atrophy Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000020763 muscle atrophy Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000008934 Muscle Proteins Human genes 0.000 claims 1
- 108010074084 Muscle Proteins Proteins 0.000 claims 1
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- BXJWDRYVBYDEJD-INIZCTEOSA-N C[C@](COc(cc1F)ccc1I)(C(Nc(cc1C(F)(F)F)ccc1N=O)=O)O Chemical compound C[C@](COc(cc1F)ccc1I)(C(Nc(cc1C(F)(F)F)ccc1N=O)=O)O BXJWDRYVBYDEJD-INIZCTEOSA-N 0.000 description 2
- LLPPSWUKHHRGQD-UHFFFAOYSA-N OC(CCOC(C(C(C(F)=C1F)F)F)=C1F)Nc(cc1C(F)(F)F)ccc1N=O Chemical compound OC(CCOC(C(C(C(F)=C1F)F)F)=C1F)Nc(cc1C(F)(F)F)ccc1N=O LLPPSWUKHHRGQD-UHFFFAOYSA-N 0.000 description 2
- 0 B*C[C@](*)(C(N*)=*)I Chemical compound B*C[C@](*)(C(N*)=*)I 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33618501P | 2001-12-06 | 2001-12-06 | |
| PCT/US2002/036147 WO2003049675A2 (en) | 2001-12-06 | 2002-12-05 | Treating muscle wasting with selective androgen receptor modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010165864A Division JP2010254707A (ja) | 2001-12-06 | 2010-07-23 | 選択的アンドロゲンレセプタ修飾因子を用いた筋萎縮治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005516002A JP2005516002A (ja) | 2005-06-02 |
| JP2005516002A5 true JP2005516002A5 (enExample) | 2006-01-05 |
| JP4605557B2 JP4605557B2 (ja) | 2011-01-05 |
Family
ID=23314937
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003550726A Expired - Fee Related JP4605557B2 (ja) | 2001-12-06 | 2002-12-05 | 選択的アンドロゲンレセプタ修飾因子を用いた筋萎縮治療 |
| JP2010165864A Pending JP2010254707A (ja) | 2001-12-06 | 2010-07-23 | 選択的アンドロゲンレセプタ修飾因子を用いた筋萎縮治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010165864A Pending JP2010254707A (ja) | 2001-12-06 | 2010-07-23 | 選択的アンドロゲンレセプタ修飾因子を用いた筋萎縮治療 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7547728B2 (enExample) |
| EP (2) | EP2289503B1 (enExample) |
| JP (2) | JP4605557B2 (enExample) |
| KR (1) | KR100767317B1 (enExample) |
| CN (1) | CN1617715B (enExample) |
| AT (1) | ATE526959T1 (enExample) |
| AU (1) | AU2002364949C1 (enExample) |
| BR (1) | BR0215115A (enExample) |
| CA (1) | CA2469340A1 (enExample) |
| CY (1) | CY1112509T1 (enExample) |
| DK (1) | DK1463497T3 (enExample) |
| EA (1) | EA007921B1 (enExample) |
| ES (1) | ES2372929T3 (enExample) |
| GE (1) | GEP20063984B (enExample) |
| HR (1) | HRP20040588A2 (enExample) |
| IL (2) | IL162340A0 (enExample) |
| MX (1) | MXPA04005519A (enExample) |
| PT (1) | PT1463497E (enExample) |
| TW (1) | TWI339118B (enExample) |
| WO (1) | WO2003049675A2 (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7759520B2 (en) | 1996-11-27 | 2010-07-20 | University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
| US6071957A (en) * | 1996-11-27 | 2000-06-06 | The University Of Tennessee Research Corporation | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer |
| US20090264534A1 (en) * | 1996-11-27 | 2009-10-22 | Dalton James T | Selective androgen receptor modulators |
| US7518013B2 (en) | 2000-08-24 | 2009-04-14 | University Of Tennessee Research Foundation | Selective androgen receptor modulators |
| US8008348B2 (en) * | 2001-12-06 | 2011-08-30 | University Of Tennessee Research Foundation | Treating muscle wasting with selective androgen receptor modulators |
| US7855229B2 (en) * | 2000-08-24 | 2010-12-21 | University Of Tennessee Research Foundation | Treating wasting disorders with selective androgen receptor modulators |
| US7622503B2 (en) | 2000-08-24 | 2009-11-24 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
| US8445534B2 (en) | 2000-08-24 | 2013-05-21 | University Of Tennessee Research Foundation | Treating androgen decline in aging male (ADAM)-associated conditions with SARMs |
| US7645898B2 (en) * | 2000-08-24 | 2010-01-12 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and method of use thereof |
| US7026500B2 (en) * | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
| US20040260108A1 (en) * | 2001-06-25 | 2004-12-23 | Dalton James T. | Metabolites of selective androgen receptor modulators and methods of use thereof |
| US7919647B2 (en) | 2000-08-24 | 2011-04-05 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
| US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
| PT1463497E (pt) * | 2001-12-06 | 2011-12-20 | Gtx Inc | Tratamento do desgaste muscular com moduladores selectivos do receptor de androgénios |
| US20070161608A1 (en) * | 2001-12-06 | 2007-07-12 | Dalton James T | Selective androgen receptor modulators for treating muscle wasting |
| JP4677516B2 (ja) | 2002-02-07 | 2011-04-27 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | Ｓａｒｍを用いた前立腺肥大症治療 |
| CA2477737C (en) * | 2002-02-28 | 2012-08-07 | The University Of Tennessee Research Corporation | Multi-substituted selective androgen receptor modulators and methods of use thereof |
| US7803970B2 (en) | 2002-02-28 | 2010-09-28 | University Of Tennessee Research Foundation | Multi-substitued selective androgen receptor modulators and methods of use thereof |
| ES2528764T3 (es) * | 2002-02-28 | 2015-02-12 | University Of Tennessee Research Foundation | Moduladores selectivos multisustituidos del receptor de andrógeno y métodos de uso de los mismos |
| EP2266577B8 (en) * | 2002-02-28 | 2015-01-21 | University Of Tennessee Research Foundation | Multi-substituted selective androgen receptor modulators and methods of use thereof |
| AU2003257863A1 (en) * | 2002-08-19 | 2004-03-03 | Nagoya Industrial Science Research Institute | Nonhuman animal reproducing pathogenic conditions of spinal and bulbar muscular atrophy and remedy for spinal and bulbar muscular atrophy |
| CN1726034A (zh) * | 2002-10-15 | 2006-01-25 | 田纳西大学研究基金会 | 亚甲基桥连的选择性雄激素受体调节剂及其应用方法 |
| US20060276539A1 (en) * | 2002-10-16 | 2006-12-07 | Dalton James T | Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS |
| WO2004035739A2 (en) * | 2002-10-16 | 2004-04-29 | Gtx, Inc. | Treating androgen decline in aging male (adam)-associated conditions with sarms |
| US8309603B2 (en) * | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| DE602004026583D1 (de) * | 2003-06-27 | 2010-05-27 | Orion Corp | Als androgenrezeptormodulatoren geeignete propionamidderivate |
| FI20030958A0 (fi) * | 2003-06-27 | 2003-06-27 | Orion Corp | Uusia yhdisteitä |
| CN100462353C (zh) * | 2003-06-27 | 2009-02-18 | 奥赖恩公司 | 用作雄激素受体调节剂的丙酰胺衍生物 |
| EP1673376A4 (en) * | 2003-10-14 | 2010-06-23 | Gtx Inc | TREATMENT OF BONE DISEASES WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS |
| EA200501761A1 (ru) * | 2003-12-16 | 2006-04-28 | Джи Ти Икс, ИНК. | Пролекарственные формы селективных модуляторов андрогеновых рецепторов и способы их применения |
| WO2005100305A1 (en) * | 2004-04-13 | 2005-10-27 | Warner-Lambert Company Llc | Androgen modulators |
| US9889110B2 (en) | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
| AU2005251781C1 (en) * | 2004-06-07 | 2008-02-21 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
| US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
| US20110237664A1 (en) * | 2004-06-07 | 2011-09-29 | Dalton James T | Selective androgen receptor modulators for treating diabetes |
| BRPI0513405A (pt) | 2004-07-16 | 2008-05-06 | Sunesis Pharmaceuticals Inc | tienopirimidinas úteis como inibidores de aurora quinase |
| US7655700B2 (en) * | 2005-08-25 | 2010-02-02 | Michigan State University | Transgenic mouse model and methods for treatment of neuro muscular disease by interfering with androgen-androgen receptor interaction in skeletal muscles |
| EA200800710A1 (ru) * | 2005-08-31 | 2008-06-30 | Юниверсити Оф Теннесси Рисерч Фаундейшн | Лечение почечной недостаточности, ожогов, ран и повреждений спинного мозга селективными модуляторами андрогенового рецептора |
| AR061980A1 (es) * | 2006-07-12 | 2008-08-10 | Univ Tennessee Res Foundation | Acilanilidas sustituidas y metodos para su utilizacion |
| KR101264820B1 (ko) | 2006-08-24 | 2013-05-22 | 유니버시티 오브 테네시 리서치 파운데이션 | 치환된 아실아닐리드 및 그의 사용 방법 |
| US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US10010521B2 (en) | 2006-08-24 | 2018-07-03 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| EA017429B1 (ru) | 2007-08-07 | 2012-12-28 | Такеда Фармасьютикал Компани Лимитед | Циклические аминные соединения |
| US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
| CA2886501C (en) * | 2007-09-11 | 2018-03-27 | Gtx, Inc. | Solid forms of selective androgen receptor modulators |
| MX2010006972A (es) | 2007-12-21 | 2010-08-26 | Ligand Pharm Inc | Moduladores selectivos de receptores de andrógenos (sarm) y usos de los mismos. |
| US9856204B2 (en) | 2010-05-20 | 2018-01-02 | University Of Iowa Research Foundation | Methods for inhibiting muscle atrophy |
| US11090313B2 (en) | 2010-05-20 | 2021-08-17 | University Of Iowa Research Foundation | Methods for inhibiting muscle atrophy |
| US8395552B2 (en) | 2010-11-23 | 2013-03-12 | Metamagnetics, Inc. | Antenna module having reduced size, high gain, and increased power efficiency |
| JP6001060B2 (ja) | 2011-06-06 | 2016-10-05 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | 筋萎縮を阻害するための方法 |
| WO2013078372A1 (en) * | 2011-11-23 | 2013-05-30 | University Of Iowa Research Foundation | Compositions and methods for inhibiting muscle atrophy and inducing muscle hypertrophy |
| US20150057452A1 (en) * | 2012-04-04 | 2015-02-26 | Catylix, Inc. | Selective androgen receptor modulators |
| US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
| JP6226978B2 (ja) | 2012-07-13 | 2017-11-08 | ジーティーエックス・インコーポレイテッド | 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）によりアンドロゲン受容体（ａｒ）陽性乳癌を処置する方法 |
| US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
| US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| JP2015071549A (ja) * | 2013-10-02 | 2015-04-16 | 株式会社ファンケル | アトロジン−１抑制剤 |
| EP3094323A4 (en) | 2014-01-17 | 2017-10-11 | Ligand Pharmaceuticals Incorporated | Methods and compositions for modulating hormone levels |
| MX2017004819A (es) * | 2014-10-16 | 2018-06-12 | Gtx Inc | Metodos de tratamiento de transtornos urológicos usando sarm. |
| KR101919081B1 (ko) * | 2017-05-11 | 2018-11-16 | (주)녹십자웰빙 | 인간 태반 추출물을 유효성분으로 포함하는 근 위축증 또는 근육감소증의 예방 또는 치료용 및 근육 기능 개선용 조성물 |
| EP3956309A4 (en) | 2019-04-19 | 2023-06-07 | Ligand Pharmaceuticals Inc. | CRYSTALLINE FORMS AND METHODS FOR PRODUCING CRYSTALLINE FORMS OF A COMPOUND |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1360001A (en) | 1971-06-16 | 1974-07-17 | Scherico Ltd | Pharmaceutical compositions comprising substituted anilides |
| US3875229A (en) * | 1972-11-24 | 1975-04-01 | Schering Corp | Substituted carboxanilides |
| JPS6044294B2 (ja) | 1976-04-15 | 1985-10-02 | 帝国臓器製薬株式会社 | アニリド誘導体 |
| US4139638A (en) * | 1976-09-23 | 1979-02-13 | Schering Corporation | Methods for the treatment of hirsutism |
| EP0002309B1 (en) | 1977-10-12 | 1982-12-01 | Imperial Chemical Industries Plc | Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them |
| US4191775A (en) * | 1977-12-15 | 1980-03-04 | Imperial Chemical Industries Limited | Amide derivatives |
| NZ197008A (en) | 1980-05-22 | 1984-10-19 | Ici Ltd | Acylanilide derivatives and pharmaceutical compositions |
| US4336505A (en) * | 1980-07-14 | 1982-06-22 | John Fluke Mfg. Co., Inc. | Controlled frequency signal source apparatus including a feedback path for the reduction of phase noise |
| JPS57171904A (en) * | 1981-04-15 | 1982-10-22 | Mitsubishi Petrochem Co Ltd | Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide |
| EP0100172B1 (en) * | 1982-07-23 | 1987-08-12 | Imperial Chemical Industries Plc | Amide derivatives |
| US4633025A (en) | 1985-04-15 | 1986-12-30 | Miles Laboratories, Inc. | Method for preparing (+)R-2-methyl-hexane-1,2-diol |
| GB8617653D0 (en) | 1986-07-18 | 1986-08-28 | Ici Plc | Amide derivatives |
| GB8617652D0 (en) * | 1986-07-18 | 1986-08-28 | Ici Plc | Acylanilide derivatives |
| US5162504A (en) * | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
| US5847076A (en) * | 1993-05-20 | 1998-12-08 | Board Of Regents, The University Of Texas System | Regulators of the proteasome |
| EP0748220A4 (en) | 1994-01-21 | 1997-09-10 | Sepracor Inc | METHOD AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R - (-) CASODEX |
| US5609849A (en) * | 1994-03-11 | 1997-03-11 | The Trustees Of The University Of Pennsylvania | Serotonin (5-HT1A) receptor ligands and imaging agents |
| DE4435368A1 (de) * | 1994-09-22 | 1996-03-28 | Schering Ag | Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann |
| US5656651A (en) * | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
| WO1998005962A1 (en) | 1996-08-02 | 1998-02-12 | Panvera Corporation | A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization |
| US6492554B2 (en) * | 2000-08-24 | 2002-12-10 | The University Of Tennessee Research Corporation | Selective androgen receptor modulators and methods of use thereof |
| US6071957A (en) * | 1996-11-27 | 2000-06-06 | The University Of Tennessee Research Corporation | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer |
| US6995284B2 (en) * | 2000-08-24 | 2006-02-07 | The University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
| US6160011A (en) * | 1997-05-30 | 2000-12-12 | The University Of Tennessee Research Corporation | Non-steroidal agonist compounds and their use in male hormone therapy |
| WO1998055153A1 (en) | 1997-06-04 | 1998-12-10 | The University Of Tennessee Research Corporation | Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging |
| US6795776B1 (en) | 1999-10-14 | 2004-09-21 | Bristol-Myers Squibb Company | Crystallographic structure of the androgen receptor ligand binding domain |
| IL149056A0 (en) | 1999-10-19 | 2002-11-10 | Nobex Corp | Methods of asymmetrically synthesizing enantiomers of casodex, its derivatives and intermediates thereof |
| CA2389100A1 (en) | 1999-10-27 | 2001-05-17 | Nobex Corporation | Resolution of intermediates in the synthesis of substantially pure bicalutamide |
| US20030069215A1 (en) * | 2001-03-30 | 2003-04-10 | The Government Of The United States Of America, | Methods of making and using 7a,11b-dimethyl-17b-hydroxy-4-estren-3-one 17b-trans-4-n-butylcyclohexane carboxylate and 7a,11b-dimethyl-17b-hydroxyestr-4-en-3-one 17-undecanoate |
| AU2001288213B2 (en) | 2000-06-28 | 2005-04-14 | Bristol-Myers Squibb Company | Selective androgen receptor modulators and methods for their identification, design and use |
| US7026500B2 (en) * | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
| ES2321933T3 (es) | 2000-08-24 | 2009-06-15 | University Of Tennessee Research Foundation | Moduladores selectivos del receptor de androgeno y metodos de uso de los mismos. |
| PT1463497E (pt) * | 2001-12-06 | 2011-12-20 | Gtx Inc | Tratamento do desgaste muscular com moduladores selectivos do receptor de androgénios |
| FI20030958A0 (fi) | 2003-06-27 | 2003-06-27 | Orion Corp | Uusia yhdisteitä |
-
2002
- 2002-12-05 PT PT02802565T patent/PT1463497E/pt unknown
- 2002-12-05 DK DK02802565.8T patent/DK1463497T3/da active
- 2002-12-05 ES ES02802565T patent/ES2372929T3/es not_active Expired - Lifetime
- 2002-12-05 WO PCT/US2002/036147 patent/WO2003049675A2/en not_active Ceased
- 2002-12-05 EP EP10075696.4A patent/EP2289503B1/en not_active Expired - Lifetime
- 2002-12-05 EA EA200400774A patent/EA007921B1/ru not_active IP Right Cessation
- 2002-12-05 JP JP2003550726A patent/JP4605557B2/ja not_active Expired - Fee Related
- 2002-12-05 KR KR1020047008659A patent/KR100767317B1/ko not_active Expired - Fee Related
- 2002-12-05 HR HR20040588A patent/HRP20040588A2/hr not_active Application Discontinuation
- 2002-12-05 AU AU2002364949A patent/AU2002364949C1/en not_active Ceased
- 2002-12-05 GE GE5641A patent/GEP20063984B/en unknown
- 2002-12-05 CN CN028279050A patent/CN1617715B/zh not_active Expired - Fee Related
- 2002-12-05 AT AT02802565T patent/ATE526959T1/de active
- 2002-12-05 BR BR0215115-4A patent/BR0215115A/pt not_active Application Discontinuation
- 2002-12-05 IL IL16234002A patent/IL162340A0/xx unknown
- 2002-12-05 US US10/310,150 patent/US7547728B2/en not_active Expired - Fee Related
- 2002-12-05 CA CA002469340A patent/CA2469340A1/en not_active Abandoned
- 2002-12-05 MX MXPA04005519A patent/MXPA04005519A/es active IP Right Grant
- 2002-12-05 EP EP02802565A patent/EP1463497B1/en not_active Expired - Lifetime
- 2002-12-06 TW TW091136268A patent/TWI339118B/zh not_active IP Right Cessation
-
2004
- 2004-06-03 IL IL162340A patent/IL162340A/en not_active IP Right Cessation
-
2010
- 2010-07-23 JP JP2010165864A patent/JP2010254707A/ja active Pending
-
2012
- 2012-01-04 CY CY20121100004T patent/CY1112509T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005516002A5 (enExample) | ||
| CA2543827A1 (en) | Selective androgen receptor modulators and methods of use thereof | |
| JP2005526741A5 (enExample) | ||
| JP2009506119A5 (enExample) | ||
| JP2024119812A5 (enExample) | ||
| JP2009542595A5 (enExample) | ||
| CN1701062A (zh) | 制备罗氟司特的新方法 | |
| JP2015505301A5 (enExample) | ||
| JP2006513268A5 (ja) | アンタゴニスト活性を有するベンゾアゾリルピペラジン誘導体 | |
| CN113365998A (zh) | 用于parp抑制剂的吲哚并七元酰肟类似物 | |
| JP2009504748A5 (enExample) | ||
| JPH02295924A (ja) | 刺激性アミノ酸拮抗剤 | |
| JP2002527474A5 (ja) | 躁病および双極性障害の治療のための医薬 | |
| JP2006503850A5 (enExample) | ||
| RU2008119692A (ru) | Новые 1-азабициклоалкилпроизводные для лечения психических растройств | |
| CA2143744A1 (en) | Diaryl piperazinoacetamide compounds as antimuscarinic agents | |
| JP2010522710A5 (enExample) | ||
| JP2013517300A5 (enExample) | ||
| JPWO2023195529A5 (enExample) | ||
| CN105228622A (zh) | 用于治疗多发性硬化的PPARγ激动剂 | |
| JP2005513017A5 (enExample) | ||
| JP2007521313A5 (enExample) | ||
| JP2006513222A5 (enExample) | ||
| JP2002512955A (ja) | 炎症疾患の治療のためのｎｍｄａアンタゴニストおよび／またはナトリウムチャンネルアンタゴニストの使用 | |
| CN103889408A (zh) | S1p受体调节剂或激动剂的剂量方案 |